He is also a Director of the College of New Jersey. and as Chairman of the Board of Directors for Rosetta Genomics, Ltd. Markison also serves on the Board of Directors of Immunomedics, Inc., on the Board of Directors of Alere Inc.
Markison held various senior leadership positions at Bristol-Myers Squibb, including President of Oncology, Virology and Oncology Therapeutics Network President of Neuroscience, Infectious Disease and Dermatology and Senior Vice President, Operational Excellence and Productivity. Markison was Chairman and Chief Executive Officer of King Pharmaceuticals, which he joined as Chief Operating Officer in March 2004, and was promoted to President and Chief Executive Officer later that year and elected Chairman in 2007. Previously, he held the position of President and Chief Executive Officer and member of the Board of Directors of Fougera Pharmaceuticals Inc., a specialty pharmaceutical company in dermatology, prior to its sale to Sandoz, the generics division of Novartis AG. He is currently the Chief Executive Officer and a Director of Osmotica Holdings, SCSp, after serving as Executive Chairman of one of its predecessor companies, Vertical/Trigen Holdings, LLC. Markison is a seasoned executive with more than 30 years of operational, marketing, commercial development and sales experience with international pharmaceutical companies. Markison has been a Healthcare Industry Executive for Avista since September 2012.
Kevin graduated from Bloomsburg University with a bachelor’s degree in business.īrian Markison is the Non-Executive Chairman of the Board of Directors since December 2019. Prior to Acerus, he worked for various Pharma companies like Endo Pharma, GE Healthcare, Syneos Health and Jazz Pharma.
He has experience with 3PL, Wholesaler and Pharmacypartners in securing product in channel and has co-led US BD activities for strategic acquisitions, co-promotions with other pharma companies and in-licensing agreements. He managed the commercial team and improved the profitability margin from 26% to 37% in the first 12 months. His last role was as SVP for the US Commercial team for Acerus Pharma where he was responsible for managing the US entity of this public Canadian pharma company. His experience includes product development, launch and commercialization, strategic planning & lifecycle management, commercial architecture design & execution, Payer landscapes, pricing strategies, distribution channels as well as portfolio P&L management. Kevin is a Commercial leader with over 17 years of experience in the pharmaceuticals industry.
0 kommentar(er)
